{
    "clinical_study": {
        "@rank": "120944", 
        "arm_group": {
            "arm_group_label": "Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)", 
            "arm_group_type": "Experimental", 
            "description": "INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.\nCONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.\nMAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well giving daunorubicin hydrochloride, cytarabine, and\n      nilotinib together works in treating patients newly diagnosed with acute myeloid leukemia.\n      Drugs used in chemotherapy, such as, daunorubicin hydrochloride and cytarabine, work in\n      different ways to stop the growth of cancer cell, either by killing the cells or by stopping\n      them from dividing. Nilotinib may stop the growth of cancer cells by blocking some of the\n      enzymes needed for cell growth. Giving daunorubicin hydrochloride together with cytarabine\n      and nilotinib may kill more cancer cells"
        }, 
        "brief_title": "Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adult Acute Basophilic Leukemia", 
            "Adult Acute Eosinophilic Leukemia", 
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "Untreated Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Basophilic, Acute", 
                "Leukemia, Eosinophilic, Acute", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Hypereosinophilic Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the complete response rates of combination nilotinib, cytarabine, and\n      daunorubicin (daunorubicin hydrochloride) in patients newly diagnosed with acute myeloid\n      leukemia (AML) and Kit overexpression.\n\n      SECONDARY OBJECTIVES:\n\n      I. Determine the 2-year overall survival (OS) and disease-free survival (DFS) rates.\n\n      II. Determine the complete response duration in patients treated with this regimen.\n\n      III. Assess the safety and toxicity of this regimen based on National Cancer Institute (NCI)\n      Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.\n\n      TERTIARY OBJECTIVES:\n\n      I. Assess the prognostic and predictive factors (Kit mutation/expression level, fms-related\n      tyrosine kinase 3 [Flt3] mutation) for patients treated with this regimen.\n\n      II. Assess the patterns of molecular response and relapse for Kit. III. Assess the effect on\n      minimal residual disease (MRD) by polymerase chain reaction (PCR) or flow cytometry.\n\n      OUTLINE:\n\n      INDUCTION THERAPY: Patients receive daunorubicin hydrochloride intravenously (IV) over 10\n      minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib orally (PO) twice\n      daily (BID)on days 4-14. Patients achieving complete remission (CR) or complete remission\n      with incomplete blood count recovery (CRi) proceed to consolidation therapy. Patients not\n      achieving a decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive\n      another course of induction therapy.\n\n      CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5,\n      and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the\n      absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi\n      proceed to maintenance therapy.\n\n      MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every\n      84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 6 months for up to 3\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Untreated, histological confirmed acute myeloid leukemia (AML) based on World Heath\n             Organization (WHO) 2008 criteria with Kit expression (cluster of differentiation [CD]\n             117) of myeloblasts >= 20% by flow cytometry from bone marrow aspirate at diagnosis\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n\n          -  Magnesium within normal limits (WNL)\n\n          -  Potassium WNL\n\n          -  Phosphorus WNL\n\n          -  Serum amylase =< 1.5 x upper limit of normal (ULN)\n\n          -  Serum lipase =< 1.5 x ULN\n\n          -  Total bilirubin =< 1.5 x ULN (does not apply to patients with isolated\n             hyperbilirubinemia [e.g., Gilbert's disease], in that case direct bilirubin should be\n             =< 2 x ULN)\n\n          -  Alkaline phosphatase =< 3 x ULN\n\n          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =<\n             3 x ULN\n\n          -  Creatinine =<1.5 x ULN\n\n          -  Negative pregnancy test done =< 7 days prior to registration, for women of\n             childbearing potential only\n\n          -  Provide informed written consent\n\n          -  Willing to return to consenting Mayo Clinic (Mayo Clinic's campus in Rochester, Mayo\n             Clinic's campus in Arizona, or Mayo Clinic's campus in Florida) institution for\n             follow-up during the active monitoring phase of the study\n\n          -  Willing to provide bone marrow aspirate and blood samples for correlative research\n             purposes\n\n        Exclusion Criteria:\n\n          -  Any of the following because this study involves investigational agent(s) whose\n             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are\n             unknown\n\n               -  Pregnant women\n\n               -  Nursing women\n\n               -  Men or women of childbearing potential who are unwilling to employ adequate\n                  contraception throughout the study and for 3 months after completion of study\n                  treatment\n\n          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the\n             judgment of the investigator, would make the patient inappropriate for entry into\n             this study or interfere significantly with the proper assessment of safety and\n             toxicity of the prescribed regimens\n\n          -  Immunocompromised patients (other than that related to the use of corticosteroids)\n             including patients known to be human immunodeficiency virus (HIV) positive\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Receiving any other investigational agent which would be considered as a treatment\n             for the primary neoplasm\n\n          -  Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic\n             skin cancer or carcinoma-in-situ of the cervix\n\n          -  Previous treatment with chemotherapy or any other tyrosine kinase inhibitor for a\n             hematological disorder; Exceptions: patients with prior diagnosis of myelodysplastic\n             syndrome (MDS) and/or treatment with hypomethylating agent (azacytidine or\n             decitabine) are not excluded, prior hydroxyurea allowed\n\n          -  Impaired cardiac function including any one of the following:\n\n               -  Inability to monitor the QT interval on electrocardiogram (ECG)\n\n               -  Congenital long QT syndrome or a known family history of long QT syndrome\n\n               -  Clinically significant resting brachycardia (< 50 beats per minute)\n\n               -  QTc > 450 msec on baseline ECG; if QTc > 450 msec and electrolytes are not\n                  within normal ranges, electrolytes should be corrected and then the patient\n                  re-screened for QTc\n\n               -  Myocardial infarction =< 2 months prior to starting study\n\n               -  Other clinically significant uncontrolled heart disease (e.g. unstable angina,\n                  congestive heart failure or uncontrolled hypertension)\n\n               -  History of or presence of clinically significant ventricular, atrial\n                  tachyarrhythmias or ejection fraction cutoff\n\n               -  Left ventricle ejection fraction < 45%\n\n               -  History of, congestive heart failure requiring use of ongoing maintenance\n                  therapy for life-threatening ventricular arrhythmias\n\n          -  Patients currently receiving treatment with strong cytochrome P450 3A4 (CYP3A4)\n             inhibitors and treatment that cannot be either discontinued or switched to a\n             different medication prior to starting study drug; patients receiving any medications\n             or substances that are strong or moderate inhibitors of CYP3A4\n\n               -  Use of the following strong or moderate inhibitors is prohibited < 7 days prior\n                  to registration\n\n                    -  Strong inhibitors of CYP3A4/5 > 5-fold increase in the plasma area under\n                       the curve (AUC) values or more then 80% decrease in clearance\n\n                         -  Boceprevir (Victrelis)\n\n                         -  Clarithromycin (Biaxin, Biaxin XL)\n\n                         -  Conivaptan (Vaprisol)\n\n                         -  Grapefruit juice\n\n                         -  Indinavir (Crixivan)\n\n                         -  Itraconazole (Sporanox)\n\n                         -  Ketoconazole (Nizoral)\n\n                         -  Lopinavir/ritonavir (Kaletra)\n\n                         -  Mibefradil\n\n                         -  Nefazodone (Serzone)\n\n                         -  Nelfinavir (Viracept)\n\n                         -  Posaconazole (Noxafil)\n\n                         -  Ritonavir (Novir, Kaletra)\n\n                         -  Saquinivir (Fortovase, Invirase)\n\n                         -  Telaprevir (Incivek)\n\n                         -  Telithromycin (Ketek)\n\n                         -  Voriconazole (Vfend)\n\n                    -  Moderate inhibitors of CYP3A4/5 > 2-fold in the plasma AUC values of\n                       50-80%, decrease in clearance\n\n                         -  Amprenavir (Agenerase)\n\n                         -  Aprepitant (Emend)\n\n                         -  Atazanavir (Reyataz)\n\n                         -  Ciprofloxacin (Cipro)\n\n                         -  Darunavir (Prezista)\n\n                         -  Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT,\n                            Dilacor XR, Diltia XT, Taztia XT, Tiazac)\n\n                         -  Erythromycin (Erythrocin, E.E.S. , Ery-Tab, Eryc, EryPed, PCE\n\n                         -  Fluconazole (Diflucan)\n\n                         -  Fosamprenavir (Lexiva)\n\n                         -  Imatinib (Gleevec)\n\n                         -  Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan\n                            PM)\n\n          -  Receiving any medications or substances that are inducers of CYP3A4; use of the\n             following inducers are prohibited =< 7 days prior to registration\n\n               -  Strong inducers of CYP3A4/5 > 80% decrease in AUC\n\n                    -  Avasimibe\n\n                    -  Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\n\n                    -  Phenytoin (Dilantin, Phenytek)\n\n                    -  Rifampin (Rifadin)\n\n                    -  St. John's wort\n\n               -  Moderate inducers of CYP3A4/5 50-80% decrease in AUC\n\n                    -  Bosentan (Tracleer)\n\n                    -  Efavirenz (Sustiva)\n\n                    -  Etravirine (Intelence)\n\n                    -  Modafinil (Provigil)\n\n                    -  Nafcillin\n\n                    -  Nevirapine (Viramune)\n\n                    -  Phenobarbital (Luminal)\n\n                    -  Rifabutin (Mycobutin)\n\n                    -  Troglitazone\n\n          -  Patients currently receiving treatment with any medications that have the potential\n             to prolong the QT interval and the treatment cannot be either discontinued or\n             switched to a different medication prior to starting study drug\n\n          -  Impaired gastrointestinal (GI) function or GI disease that may significantly alter\n             the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea,\n             vomiting, diarrhea, malabsorption syndrome, small bowel resection or gastric bypass\n             surgery)\n\n          -  Acute or chronic pancreatic disease\n\n          -  Known cytopathologically confirmed central nervous system (CNS) infiltration\n\n          -  Acute or chronic liver disease or severe renal disease considered unrelated to the\n             cancer\n\n          -  History of significant congenital or acquired bleeding disorder unrelated to cancer\n\n          -  Major surgery =< 4 weeks prior to registration of the study or who have not recovered\n             from prior surgery\n\n          -  Treatment with other investigational agents =< 14 days of registration\n\n          -  Diagnosis of AML-M3 (or acute promyelocytic leukemia)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806571", 
            "org_study_id": "MC1284", 
            "secondary_id": "NCI-2013-00469"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)", 
                "description": "Given IV", 
                "intervention_name": "daunorubicin hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cerubidin", 
                    "Cerubidine", 
                    "daunomycin hydrochloride", 
                    "daunorubicin", 
                    "RP-13057"
                ]
            }, 
            {
                "arm_group_label": "Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)", 
                "description": "Given IV", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)", 
                "description": "Given PO", 
                "intervention_name": "nilotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AMN 107", 
                    "Tasigna"
                ]
            }, 
            {
                "arm_group_label": "Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Daunorubicin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 30, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Mayo Clinic Clinical Trials Referral Office", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Mayo Clinic in Arizona"
                }, 
                "investigator": {
                    "last_name": "Raoul Tibes, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alkali.aref@mayo.edu", 
                    "last_name": "Mayo Clinic Clinical Trials Referral Office", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Aref Al-Kali, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Aref Al-Kali, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner (Duffy D 1987).", 
            "measure": "Proportion of complete responses (CR or CRi) during induction therapy", 
            "safety_issue": "No", 
            "time_frame": "Up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806571"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Aref Al-Kali", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The distribution of survival time will be estimated using the method of Kaplan-Meier (Kaplan E 1958).", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From registration to death due to any cause, assessed up to 3 years"
            }, 
            {
                "measure": "OS rate", 
                "safety_issue": "No", 
                "time_frame": "At 2 years"
            }, 
            {
                "description": "The distribution of DFS will be estimated using the method of Kaplan- Meier.", 
                "measure": "Disease-free survival time (DFS)", 
                "safety_issue": "No", 
                "time_frame": "From registration to relapse or death due to any cause, assessed up to 3 years"
            }, 
            {
                "measure": "DFS rate", 
                "safety_issue": "No", 
                "time_frame": "At 2 years"
            }, 
            {
                "description": "The distribution of duration of complete response will be estimated using the method of Kaplan-Meier.", 
                "measure": "Duration of complete response", 
                "safety_issue": "No", 
                "time_frame": "From the date at which objective status is first noted to be CR or CRi to the earliest date relapse is documented, assessed up to 3 years"
            }, 
            {
                "description": "The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability assessed by NCI CTCAE version 4.0 out to 3 years", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years after completion of study treatment"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}